Anmeldelse af 'Emerek, Ruth ; Kold, Vibeke ; Ipsen, Sanne ; Holt, Helle (red.): Brydninger:Perspektiver på det kønsopdelte arbejdsmarked'

Autor: Fiig, Hanne Christina

Publikováno v: Fiig, H C 1998, ' Anmeldelse af "Emerek, Ruth ; Kold, Vibeke ; Ipsen, Sanne ; Holt, Helle (red.): Brydninger : Perspektiver på det kønsopdelte arbejdsmarked" ', Kvinder, Køn og forskning, bind årg. 7, nr. 2, s. 98-100 .

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::09b0441f3a2d35f50b1caeb2fe9abf18
https://vbn.aau.dk/da/publications/e972a6e0-8091-11db-8b97-000ea68e967b

Abstract 922: End-to-end discovery to support the development of safe and efficacious engineered cell therapies

Autor: Sanne Holt, Sawsan Youssef, Sophie Vermond, Jake Glanville, Katherine Vousden, Monique Hazenoot, Sarah Ives

Publikováno v: Cancer Research. 81:922-922

The global market for cell and gene therapies, including T-cell/Natural Killer cell chimeric antigen receptors (CAR-T/NK), is continuing to grow rapidly - with many clinical success stories for B-cell malignancies in particular. However, the path to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b77def67995ee8f829ca135be18f20e9
https://doi.org/10.1158/1538-7445.am2021-922

142 Enhanced antitumoral activity of HER2-CAR-Ts in comparison to trastuzumab in a live cell imaging supported 3D assay

Autor: Gemma Moiset, Julia Schüler, Katharina Schaich, Kanstantsin Lashuk, Sophie Vermond, Sanne Holt, Monique Hazenoot, Eva Oswald

Publikováno v: Journal for ImmunoTherapy of Cancer. 9:A150-A150

BackgroundAlthough most breast cancer patients are treated these days with a curative intention, there are still many patients progressing to metastatic disease. The advent of anti-HER2 therapy has prominently prolonged the time of disease progressio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::50a5696048f4282819980b4d5e4b864c
https://doi.org/10.1136/jitc-2021-sitc2021.142

Abstract 6705: An integrated in vitro and in vivo approach providing insights in immune modulation

Autor: Omar Aziz, Ian D. Waddell, Julia Schüler, Sanne Holt, Jeroen DeGroot, Shilina Roman

Publikováno v: Cancer Research. 80:6705-6705

In order to exploit the complex tumour microenvironment, immunoreactivity in a multitude of cell-based assays is required to predict mode of action (MOA), pharmacodynamics, and efficacy downstream. We have developed an integrated approach starting wi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::33f1f9bc93c5c1f76fd399d1f69ebf15
https://doi.org/10.1158/1538-7445.am2020-6705

Abstract 1373: Primary or iPSC-derived cell-based cytotoxicity assays to assess potential safety risks of engineered T cell therapies in vitro

Autor: Marijn Vlaming, Monique Hazenoot, Sophie Vermond, Rene McLaughlin, Sanne Holt, Marco Guadagnoli

Publikováno v: Cancer Research. 81:1373-1373

Engineered T cell therapies, such as Chimeric Antigen Receptor (CAR) and T Cell Receptor (TCR) T cells, but also bi-specific antibody therapies, play a major role in the field of immuno-oncology and offer great promise in becoming a new wave of highl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::34b7894afec997ceb77debe25eaecb93
https://doi.org/10.1158/1538-7445.am2021-1373